For some families, the year after childbirth may not only mean loads of diapers but stacks of unpaid medical bills as well.
Bristol Myers makes a $4.8B bet on KRAS, striking deal to acquire Mirati
Bristol Myers Squibb has signed a $4.8 billion deal to buy Mirati Therapeutics and its cancer drug Krazati, which targets what was once thought to